RBC transfusion requirements after allogeneic marrow transplantation: impact of the before‐transplant Hb level on transfusion and early survival

BACKGROUND : Most patients undergoing allogeneic marrow transplantation (alloBMT) require transfusions of RBCs. A retrospective analysis was performed to evaluate the utilization and risk factors for RBC transfusions including age and sex of recipient, HLA matching between donor and recipient, disease status at time of BMT, the occurrence of GVHD, ABO blood group compatibility, the source of progenitor cells and the Hb level before BMT (PT‐Hb).

[1]  O. Ringdén,et al.  Blood transfusion in marrow graft recipients , 1992, Annals of Hematology.

[2]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[3]  J. Caro,et al.  Anemia as an independent prognostic factor for survival in patients with cancer , 2001 .

[4]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[6]  C. D. de Souza,et al.  A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. , 2001, Haematologica.

[7]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Aranha,et al.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.

[9]  G. Dranitsaris,et al.  Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective , 1998, Bone Marrow Transplantation.

[10]  D. Henry.  Haematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Szer,et al.  Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. , 1995, Bone marrow transplantation.

[12]  P. Ljungman,et al.  Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. , 1994, Bone marrow transplantation.

[13]  M. Goldberg,et al.  Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. , 1994, Blood.

[14]  F. Mandelli,et al.  A controlled trial of recombinant human erythropoietin after bone marrow transplantation. , 1994, Blood.

[15]  M. Otero,et al.  Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. , 1992, Bone marrow transplantation.

[16]  R. Storb,et al.  Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission. , 1989, Bone marrow transplantation.

[17]  A. Gratwohl,et al.  Hematological support in patients undergoing allogenetic bone marrow transplantation. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  I. Sniecinski,et al.  Immunohematologic problems arising from ABO incompatible bone marrow transplantation. , 1987, Transplantation proceedings.

[19]  P. Martin,et al.  Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor. , 1987, Experimental hematology.

[20]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[21]  P. Warkentin.  Transfusion of patients undergoing bone marrow transplantation. , 1983, Human pathology.

[22]  J. Curtis,et al.  Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility. , 1982, Canadian Medical Association journal.

[23]  H. Braine,et al.  Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion. , 1982, Blood.

[24]  R. Storb,et al.  Transfusion problems associated with transplantation. , 1981, Seminars in hematology.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .